340B Drug Pricing Program

AHA March 12 released a new report from Healthsperien on discounts to 340B hospitals through the 340B Drug Pricing Program relative to drug company revenues and revenue growth.
The U.S. Court of Appeals for the 8th Circuit March 12 upheld Arkansas’ 340B Drug Pricing Nondiscrimination Act against a constitutional challenge brought by the Pharmaceutical Research and Manufacturers of America, ruling that the Federal Food, Drug, and Cosmetic Act does not preempt the state law.
The 340B Drug Pricing Program allows hospitals caring for large numbers of underserved patients to stretch scarce federal resources and provide more comprehensive care by requiring drug companies to offer discounted prices on certain outpatient drugs.
AHA Feb. 29 filed a friend-of-the-court brief in support of a Louisiana law that prohibits drug companies from denying Louisiana hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies, its latest in a string of lawsuits claiming…
On Feb. 2, a bipartisan group of six senators released a draft bill called the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act.
On Feb. 2, a bipartisan group of six senators released a draft bill called the Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act.
The AHA 340B Alliance Feb. 22 at 3 p.m. ET will host a call for AHA members about a discussion draft of legislation to provide “clarity, transparency and accountability to the 340B program.”
A new study published in the New England Journal of Medicine demonstrates a stunning lack of understanding of the 340B drug pricing program and the overall landscape of drug pricing.